Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion ...

Remibrutinib results in significant improvement in patients still symptomatic after second-generation H1-antihistamine treatment.

Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch ...

In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on ...

Urticaria is the medical term for hives. Sometimes hives are confused for other skin conditions such as eczema or rosacea, but their appearance and cause set them apart. There are specific ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

The U.S. Consumer Product Safety Commission has recalled 2,300 bottles of a Benadryl product due to its lack of child ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of these symptoms) for more than 6 weeks. Remibrutinib, an oral ...